Bayer predicted on Tuesday its experimental drug against dangerous blood clots could make more than 5 billion euros ($5.4 billion).
Asundexian is designed to prevent thrombosis and strokes, and belongs to a novel class of drugs known as factor XI inhibitors, which has also attracted Novartis and its partner, private equity firm Blackstone.
Another close contestant in the factor XI race is Bristol-Myers Squibb, headquartered in New York City, which is working with Johnson & Johnson.
https://www.reuters.com/business/healthcare-pharmaceuticals/bayer-flags-new-blood-thinner-5-bln-plus-opportunity-2023-01-10/
[ + ] usedoilanalysis
[ - ] usedoilanalysis 1 point 2.3 yearsJan 11, 2023 09:06:10 ago (+1/-0)
[ + ] mxcviel
[ - ] mxcviel [op] 1 point 2.3 yearsJan 11, 2023 09:42:35 ago (+1/-0)
well aspirin works on different level, with similar end effect...
But this is a nice proof that vaccines (or virus) can cause blood clots is such extent, that will be $5bln business.